[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100514481":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":67,"collaborators":19,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":19,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":19,"enrollmentInfo":79,"targetDuration":19,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":95,"overallStatus":36,"whyStopped":19,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Northwell Health","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Laparoscopically harvested omental tissue autograft","EXPERIMENTAL","Use of laparoscopically harvested omental autografts into the resection cavity of recurrent glioblastoma multiforme (rGBM) patients.",[13],"Procedure: Laparoscopically harvested omental tissue autograft",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"PROCEDURE","1. Standard neurosurgical removal of recurrent GBM,\n2. removal of fat from abdomen called omentum using a thin tube with a camera (laparoscopically),\n3. the omental fat will be transferred and implanted into brain tumor cavity,\n4. standard closure of surgical resection cavity.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"John Boockvar, MD","PRINCIPAL_INVESTIGATOR",[25,29],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","212-434-3900","jboockvar@northwell.edu",{"name":30,"role":26,"phone":31,"phoneExt":19,"email":32},"Tamika Wong, MPH","212-434-4836","twong4@northwell.edu",[34],{"facility":35,"status":36,"city":37,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Lenox Hill Brain Tumor Center","RECRUITING","New York","10075","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-74.00597,40.71427,{"lat":45,"lon":44},[48,49,50,51,54,56,58,60,61,63,65],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},{"name":30,"role":26,"phone":31,"phoneExt":19,"email":32},{"name":22,"role":23,"phone":19,"phoneExt":19,"email":19},{"name":52,"role":53,"phone":19,"phoneExt":19,"email":19},"David Langer, MD","SUB_INVESTIGATOR",{"name":55,"role":53,"phone":19,"phoneExt":19,"email":19},"Robert A Andrews, MD",{"name":57,"role":53,"phone":19,"phoneExt":19,"email":19},"Netanel Ben-Shalom, MD",{"name":59,"role":53,"phone":19,"phoneExt":19,"email":19},"Avraham Zlochower, MD",{"name":30,"role":53,"phone":19,"phoneExt":19,"email":19},{"name":62,"role":53,"phone":19,"phoneExt":19,"email":19},"Vadim Zhigin, PA-C",{"name":64,"role":53,"phone":19,"phoneExt":19,"email":19},"Olivia Albers, NP",{"name":66,"role":53,"phone":19,"phoneExt":19,"email":19},"Amy McKeown, NP",{"type":23,"investigatorFullName":68,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"John Boockvar, MD Zucker SOM @Hofstra\u002FNorthwell","Principal Investigator","100514481","omental-tissue-autograft-in-human-recurrent-glioblastoma-multiforme-rgbm-100514481",false,"NCT05979064","Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)","Laparoscopically Harvested Omental Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)","Inclusion Criteria:\n\n1. Subject is a male or female 18 years of age or older.\n2. Subject is undergoing planned resection of known or suspected GBM.\n3. Subject has a Karnofsky Performance Status (KPS) 70% or greater.\n4. Subject has a life expectancy of at least 6 months, in the opinion of the Investigator.\n5. Based on the pre-operative evaluation by neurosurgeon, the subject is a candidate for ≥ 80% resection of enhancing region.\n6. Subject must be able to undergo MRI evaluation.\n7. Subject meets the following laboratory criteria:\n\n   1. White blood count ≥ 3,000\u002FμL\n   2. Absolute neutrophil count ≥ 1,500\u002FμL\n   3. Platelets ≥ 100,000\u002FμL\n   4. Hemoglobin \\> 10.0 g\u002FdL (transfusion and\u002For ESA allowed)\n   5. Total bilirubin and alkaline phosphatase ≤ 2x institutional upper limit of normal (ULN)\n   6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C 3 x ULN\n   7. Blood urea nitrogen (BUN) and creatinine \\\u003C 1.5 x ULN\n8. Females of reproductive potential must have a negative serum pregnancy test and be willing to use an acceptable method of birth control.\n9. Able to understand and willing to sign an institutional review board (IRB)- approved written informed consent document\n\nInclusion criteria considered during surgery:\n\n1. Subject has a histologically confirmed (frozen section) diagnosis of recurrent WHO Grade IV glioblastoma multiforme (GBM).\n2. Omental graft is technically feasible.\n\nExclusion Criteria:\n\n1. Subject, if female, is pregnant or is breast feeding.\n2. Subject intends to participate in another clinical trial.\n3. Subject intends to undergo treatment with the Gliadel® wafer at the time of this surgery.\n4. Subject has an active infection requiring treatment.\n5. Subject has radiographic evidence of multi-focal disease or leptomeningeal dissemination.\n6. Subject has a history of other malignancy, unless the patient has been disease- free for at least 5 years. Adequately treated basal cell carcinoma or squamous cell skin cancer is acceptable regardless of time, as well as localized prostate carcinoma or cervical carcinoma in situ after curative treatment\n7. Subject has a known positive test for human immunodeficiency virus infection, or active hepatitis B or hepatitis C infection.\n8. Subject has a history or evidence of any other clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.\n9. Subject has had prior abdominal surgery that in the opinion of the general surgeon makes removal of omentum more risky or inadequate.\n10. Subject has severe renal insufficiency rendering gadolinium MRI contraindicated.\n11. Subject who are unable to have an MRI scan for any reason.","ALL","18 Years",{"count":80,"type":81},10,"ESTIMATED","INTERVENTIONAL",[84],"NA","This single center, single arm, open-label, phase I study will assess the safety of laparoscopically harvested autologous omentum, implanted into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.",[87,88,89,90,91,92,93,94],"Glioma","Glioma, Malignant","Glioblastoma","Glioblastoma Multiforme","Glioblastoma Multiforme of Brain","GBM","Brain Cancer","High Grade Glioma",[96,97,98,99,100],"blood brain barrier","omentum autograft","omental autograft","omentum","omental","2026-05-28",{"date":103,"type":104},"2026-06-01","ACTUAL",{"date":106,"type":104},"2023-04-04",{"date":108,"type":81},"2028-04",{"name":5,"class":6},1]